Dr. Reddy’s Laboratories Receives Mixed USFDA Inspection Updates: Form 483 in Hyderabad, Favorable VAI in UK

Dr. Reddy’s Laboratories Limited has provided updates on two recent Good Manufacturing Practices (GMP) inspections conducted by the United States Food & Drug Administration (USFDA) at its global facilities, reflecting a mix of routine regulatory observations and strong compliance. Key Inspection Outcomes: Bachupally, Hyderabad (Formulations - FTO-3): The USFDA concluded an inspection (August 6–14, 2026) and issued a Form 483 with four observations. The company has acknowledged the findings and committed to addressing them diligently within the stipulated regulatory timelines to ensure uninterrupted operations for the U.S. market. Mirfield, United Kingdom (API Manufacturing): The USFDA classified the inspection outcome as ‘Voluntary Action Indicated’ (VAI). This is a favorable regulatory designation indicating that no significant regulatory action is required, and the inspection has been officially closed. Strategic & Regulatory Outlook: These updates highlight the routine nature of global regulatory oversight for major pharmaceutical manufacturers. While the Form 483 at the Hyderabad facility requires prompt remediation—a standard occurrence in the industry—the favorable VAI status at the UK API facility reinforces the company’s robust quality systems. Dr. Reddy’s proactive approach to addressing the Hyderabad observations will be key to maintaining seamless supply chains and regulatory standing in the critical U.S. generics market. $DRREDDY